OOIR: Observatory of International Research

Papers

(The TQCC of European Heart Journal-Cardiovascular Pharmacotherapy is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
Comments on—The noradrenaline dosing in the new 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure	69
Anticoagulation for the prevention of arterial thromboembolism in cancer patients by primary tumour site: a systematic review and meta-analysis of randomized trials	64
The search for the holy grail: the balance between the risk of thrombosis and bleeding in patients	56
Associations of omega-3 fatty acids vs. fenofibrate with adverse cardiovascular outcomes in people with metabolic syndrome: propensity matched cohort study	56
Effects of renin–angiotensin system blockers on outcomes from COVID-19: a systematic review and meta-analysis of randomized controlled trials	48
Prognostic benefit of glucagon-like peptide-1 receptor agonists addition to sodium-glucose cotransporter 2 inhibitors in patients with atherosclerotic cardiovascular disease and heart failure: a cohor	42
Early initiation of SGLT2 inhibitors after acute myocardial infarction	38
Sex-related differences in cardiovascular pharmacotherapy: fiction or fact? . Why can't we see the evidence?	35
Interdisciplinary recommendations for recurrent hyperkalaemia: insights from the GUARDIAN-HK European Steering Committee	34
Comparative cardiovascular and renal effectiveness of empagliflozin and dapagliflozin: Scandinavian cohort study	33
Net clinical benefit of extended dual pathway inhibition according to baseline risk in patients with chronic coronary syndrome: a COMPASS substudy	31
Current evidence and future perspective for the management of left-sided prosthetic valve thrombosis	31
Impact of transfusion strategy on platelet aggregation and biomarkers in myocardial infarction patients with anemia	30
Edoxaban for 12 vs. 3 months in cancer-associated isolated distal deep vein thrombosis according to different doses: insights from the ONCO DVT study	29
Editorial on incidence and outcomes of transient new onset atrial fibrillation complicating acute coronary syndromes: results from a systematic review and meta-analysis	28
Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlle	27
Need for more evidence of safety in the pharmacological therapy of anaemia in chronic kidney disease: a cardiovascular perspective	27
Treatment with dual antiplatelet therapy after an acute coronary event may often be tailor-made for the patient	27
Flecainide to prevent atrial arrhythmia after patent foramen ovale closure, Rationale and design of the randomized AFLOAT study	26
Management of patients with congenital bleeding disorders and cardiac indications for antithrombotic therapy	24
Subcutaneous furosemide patch: heart failure decongestion ‘from the comfort of your home’	23
All about clinical trials	23
Inhibition of interleukin-1 or -6 after myocardial infarction: pros, cons, and future perspectives	22
Safety and efficacy of early initiation of sodium-glucose cotransporter-2 inhibitors after an acute coronary syndrome event: a meta-analysis of randomized controlled trials	22
Cardiac adverse drug reactions to COVID-19 vaccines. A cross-sectional study based on the Europe-wide data	22

Efficacy and safety of P2Y12 inhibitor monotherapy after complex PCI: a collaborative systematic review and meta-analysis	21
Anti-inflammatory pharmacotherapy in patients with cardiovascular disease	20
Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy	20
De-escalation versus shortening of dual antiplatelet therapy	19
New ways of mitigating aldosterone in cardiorenal disease	19
Late breaking clinical trials at ACC 22	19
Long-term effects of phosphodiesterase-5 inhibitors on cardiovascular outcomes and death: a systematic review and meta-analysis	18
Cardiovascular prevention and risk factors	18
Long-term antiplatelet monotherapy after PCI: searching for the smart choice	18
Association of guideline-directed medical therapy adherence with outcomes after fractional flow reserve-based deferral of revascularization	18
Antithrombotic therapy and cardiovascular outcomes after transcatheter aortic valve implantation in patients without indications for chronic oral anticoagulation: a systematic review and network meta-	18
Impact of left ventricular ejection fraction on the effect of beta-blocker therapy on one-year mortality in acute coronary syndrome patients	18
Correction to: Aspirin-free strategy for percutaneous coronary intervention in acute coronary syndrome based on the subtypes of acute coronary syndrome and high bleeding risk: the STOPDAPT-3 trial	17
News in cardiovascular pharmacotherapy from the ACC.24 Meeting	17
Effectiveness and safety of rivaroxaban vs. apixaban in patients with atrial fibrillation and peripheral artery disease	17
Focus on different lipid-lowering treatment and genetic testing for optimal pharmacotherapy use in the clinic	16
Pharmacotherapy of patients with heart failure and atrial fibrillation: let's get the evidence!	16
Adenosine as adjunctive therapy in acute coronary syndrome: a meta-analysis of randomized controlled trials	15
Entering a new era of antiplatelet therapy: the 4D-ACS trial	15
Chronic coronary syndrome and new-onset atrial fibrillation or venous thromboembolism: how best to manage antithrombotic therapy strategies	15
Dronedarone vs. placebo in patients with atrial fibrillation or atrial flutter across a range of renal function: apost hocanalysis of the ATHENA trial	15
The dual endothelin-1 antagonist aprocitentan alleviates mitochondrial oxidative stress in human cardiac fibroblasts	15
Apixaban outcomes in atrial fibrillation patients with a single-dose reduction criterion: ASPIRE 1-year results	15
Stroke risk stratifications according to CHA2DS2-VASc vs. CHA2DS2-VA in patients with atrial fibrillation: insights from the GLORIA-AF registry	14
Are NOACs always the best strategy in elderly AF patients?	14
Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis	14
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2023	14
Photoinduced skin reactions of cardiovascular drugs—a systematic review	14
Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban: Observations from the prospective EMIR Registry	13
Efficacy of new medical therapies in patients with heart failure, reduced ejection fraction, and chronic kidney disease already receiving neurohormonal inhibitors: a network meta-analysis	13
Effects of renin–angiotensin system inhibitor type and dosage on survival after transcatheter aortic valve implantation	13
Focus on different aspects of atrial fibrillation	13
Association of PCSK9 inhibitors with mortality: insights from a retrospective cohort analysis	12
Is the TIME study on antihypertensive therapy and chronotropic effects on cardiovascular outcomes a pragmatic trial?	12
Initial statin dose after myocardial infarction and long-term cardiovascular outcomes	12
Cardiovascular outcomes in hepatitis C virus infected patients treated with direct acting antiviral therapy: a retrospective multi-institutional study	12
Effectiveness and safety of direct oral anticoagulation vs. warfarin in frail patients with atrial fibrillation	12
What's new in pharmacotherapy at ESC Congress 2023?	12
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2022	12
Cardiovascular disease and cardiovascular pharmacotherapy: the challenges and the research continue	11
Immunomodulatory effect of different statin regimens on regulatory T-cells in patients with acute coronary syndrome: a systematic review and network meta-analysis of randomized clinical trials	11
Who requires longer-term anticoagulation therapy for venous thromboembolism from the perspective of precision medicine?	11
New-onset syncope in diabetic patients treated with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors: a Chinese population-based cohort study	11
Inotropes and mortality in patients with cardiogenic shock: an instrumental variable analysis from the SWEDEHEART registry	11
Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapy	11
Extensive LDL-cholesterol lowering by PCSK9 inhibitor on the risk of venous thrombosis	11
Dual antiplatelet therapy duration after percutaneous coronary intervention in patients with indication to oral anticoagulant therapy. A systematic review and meta-analysis of randomized controlled tr	10
Does LDL-C determination method affect statin prescribing for primary prevention? A register-based study in Southern Denmark	10
Effect of SGLT2i on kidney outcomes of individuals with type 2 diabetes according to body mass index: nationwide cohort study	10
Corrigendum to: Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharm	10

Use of methylphenidate is associated with increased risk of out-of-hospital cardiac arrest in the general population: a nationwide nested case-control study	10
Impact of body mass on P2Y12-inhibitor de-escalation in acute coronary syndromes—a substudy of the TROPICAL-ACS trial	10
An aspirin-free strategy for percutaneous coronary intervention in patients with diabetes: a pre-specified subgroup analysis of the STOPDAPT-3 trial	10
Use of proton pump inhibitors is associated with increased risk of out-of-hospital cardiac arrest in the general population: a nested case-control study	10
Treating patients with anticoagulants and antiplatelet drugs is always a balance between risk for thrombosis vs. risk for bleeding	9
FLOW trial stopped early due to evidence of renal protection with semaglutide	9
Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease	9
We have much more to learn about sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists	9
Response to—Current evidence and future perspective for the management of left sided prosthetic valve thrombosis	9
RNA-targeted therapeutics in cardiovascular disease: the time is now	9
Sodium–glucose cotransporter 2 inhibitor use in early-phase acute coronary syndrome with severe heart failure	9
The role of inotropes in cardiogenic shock: to help, to harm or do nothing at all?	8
Tolerability and efficacy of sodium-glucose co-transporter 2 inhibitors in patients with cardiac amyloidosis: a meta-analysis of observational studies	8
The ESC Working Group on cardiovascular pharmacotherapy: continuity through transformation	8
2024 ESC Guidelines for the management of elevated blood pressure and hypertension: what is new in pharmacotherapy?	8
Cardiovascular risks of continuing vs. initiating NSAIDs after first-time myocardial infarction or heart failure: a nationwide cohort study	8
Corrigendum to: Association between use of novel glucose-lowering drugs and COVID-19 hospitalization and death in patients with type 2 diabetes: A nationwide registry analysis	8
News in cardiovascular pharmacotherapy from the ACC.25 Meeting	8
Fenofibrate therapy and risk of heart failure outcomes in patients with Type 2 diabetes: a propensity-matched cohort study	8